Benign prostatic hyperplasia

Part 2-management

Timothy J Wilt, James N'Dow

Research output: Contribution to journalArticle

9 Citations (Scopus)
3 Downloads (Pure)

Abstract

Treatment should improve patients’ symptoms and reduce progression and need for surgery while minimising harms and costs. Management includes observation, lifestyle modification, drug treatment, minimally invasive surgery, and surgical removal of prostate tissue. a blockers are the most effective drug for improving lower urinary tract symptoms and short term quality of life.
Combination treatment (a blockers and 5a-reductase inhibitors) reduces progression of benign prostatic hyperplasia and need for surgery if the symptoms are moderate or severe and the prostate glands large, if taken for more than a year; adverse events increase. 5a-reductase inhibitors may reduce risk of prostate cancer but may increase the risk of high grade disease. Transurethral resection of the prostate results in the greatest improvement in symptoms and flow rate, but adverse effects include the risk of surgery. Minimally invasive surgery can provide benefits comparable to transurethral resection of the prostate, with fewer serious adverse effects. Short term repeat intervention and urinary retention rates are higher than with transurethral resection of the prostate. Long term effect is unclear.
Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalBritish Medical Journal
Volume336
Issue number7637
DOIs
Publication statusPublished - 26 Jan 2008

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Minimally Invasive Surgical Procedures
Prostate
Oxidoreductases
Lower Urinary Tract Symptoms
Urinary Retention
Pharmaceutical Preparations
Life Style
Prostatic Neoplasms
Therapeutics
Quality of Life
Observation
Costs and Cost Analysis

Cite this

Benign prostatic hyperplasia : Part 2-management. / Wilt, Timothy J; N'Dow, James.

In: British Medical Journal, Vol. 336, No. 7637, 26.01.2008, p. 206-210.

Research output: Contribution to journalArticle

Wilt, Timothy J ; N'Dow, James. / Benign prostatic hyperplasia : Part 2-management. In: British Medical Journal. 2008 ; Vol. 336, No. 7637. pp. 206-210.
@article{070551dfc76740c9af8edd4cb30cb08c,
title = "Benign prostatic hyperplasia: Part 2-management",
abstract = "Treatment should improve patients’ symptoms and reduce progression and need for surgery while minimising harms and costs. Management includes observation, lifestyle modification, drug treatment, minimally invasive surgery, and surgical removal of prostate tissue. a blockers are the most effective drug for improving lower urinary tract symptoms and short term quality of life. Combination treatment (a blockers and 5a-reductase inhibitors) reduces progression of benign prostatic hyperplasia and need for surgery if the symptoms are moderate or severe and the prostate glands large, if taken for more than a year; adverse events increase. 5a-reductase inhibitors may reduce risk of prostate cancer but may increase the risk of high grade disease. Transurethral resection of the prostate results in the greatest improvement in symptoms and flow rate, but adverse effects include the risk of surgery. Minimally invasive surgery can provide benefits comparable to transurethral resection of the prostate, with fewer serious adverse effects. Short term repeat intervention and urinary retention rates are higher than with transurethral resection of the prostate. Long term effect is unclear.",
author = "Wilt, {Timothy J} and James N'Dow",
year = "2008",
month = "1",
day = "26",
doi = "10.1136/bmj.39433.670718.AD",
language = "English",
volume = "336",
pages = "206--210",
journal = "BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7637",

}

TY - JOUR

T1 - Benign prostatic hyperplasia

T2 - Part 2-management

AU - Wilt, Timothy J

AU - N'Dow, James

PY - 2008/1/26

Y1 - 2008/1/26

N2 - Treatment should improve patients’ symptoms and reduce progression and need for surgery while minimising harms and costs. Management includes observation, lifestyle modification, drug treatment, minimally invasive surgery, and surgical removal of prostate tissue. a blockers are the most effective drug for improving lower urinary tract symptoms and short term quality of life. Combination treatment (a blockers and 5a-reductase inhibitors) reduces progression of benign prostatic hyperplasia and need for surgery if the symptoms are moderate or severe and the prostate glands large, if taken for more than a year; adverse events increase. 5a-reductase inhibitors may reduce risk of prostate cancer but may increase the risk of high grade disease. Transurethral resection of the prostate results in the greatest improvement in symptoms and flow rate, but adverse effects include the risk of surgery. Minimally invasive surgery can provide benefits comparable to transurethral resection of the prostate, with fewer serious adverse effects. Short term repeat intervention and urinary retention rates are higher than with transurethral resection of the prostate. Long term effect is unclear.

AB - Treatment should improve patients’ symptoms and reduce progression and need for surgery while minimising harms and costs. Management includes observation, lifestyle modification, drug treatment, minimally invasive surgery, and surgical removal of prostate tissue. a blockers are the most effective drug for improving lower urinary tract symptoms and short term quality of life. Combination treatment (a blockers and 5a-reductase inhibitors) reduces progression of benign prostatic hyperplasia and need for surgery if the symptoms are moderate or severe and the prostate glands large, if taken for more than a year; adverse events increase. 5a-reductase inhibitors may reduce risk of prostate cancer but may increase the risk of high grade disease. Transurethral resection of the prostate results in the greatest improvement in symptoms and flow rate, but adverse effects include the risk of surgery. Minimally invasive surgery can provide benefits comparable to transurethral resection of the prostate, with fewer serious adverse effects. Short term repeat intervention and urinary retention rates are higher than with transurethral resection of the prostate. Long term effect is unclear.

U2 - 10.1136/bmj.39433.670718.AD

DO - 10.1136/bmj.39433.670718.AD

M3 - Article

VL - 336

SP - 206

EP - 210

JO - BMJ

JF - BMJ

SN - 0959-8146

IS - 7637

ER -